Algiax Pharmaceuticals
Germany - ErkrathPharmaceutical
Focus: Algiax Pharmaceuticals is a Germany-based pharmaceutical company focused on small molecule GABA-a receptor modulators for neurological disorders. The company is early-stage with a single Phase 2 program in peripheral post-surgical neuropathic pain.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Algiax Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Algiax Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 2
Clinical Trials (2)
NCT05160272Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes
Phase 2Help build intelligence for Algiax Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.